血小板裂解物促进间充质干细胞扩增:细胞治疗应用中动物血清的安全替代品。
Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications.
作者信息
Doucet Christelle, Ernou Isabelle, Zhang Yizhou, Llense Jean-Roch, Begot Laurent, Holy Xavier, Lataillade Jean-Jacques
机构信息
Département Recherches, Centre de Transfusion Sanguine des Armées Jean Julliard, Clamart Cedex, France.
出版信息
J Cell Physiol. 2005 Nov;205(2):228-36. doi: 10.1002/jcp.20391.
Mesenchymal stem cells (MSCs) are considered as emergent "universal" cells and various tissue repair programs using MSCs are in development. In vitro expansion of MSCs is conventionally achieved in medium containing fetal calf serum (FCS) and is increased by addition of growth factors. However, for widespread clinical applications, contact of MSCs with FCS must be minimized since it is a putative source of prion or virus transmission. Therefore, because platelets are a natural source of growth factors, we sought to investigate in vitro MSC expansion in response to platelet lysates (PL) obtained from platelet-rich plasma. Human MSCs were expanded in FCS (+/-bFGF)- or PL-supplemented medium through a process of subculture. We demonstrated that PL-containing medium is enriched by growth factors (platelet-derived growth factors (PDGFs), basic fibroblast growth factor (bFGF), transforming growth factor (TGF-beta), insulin-like growth factor-1 (IGF-1) ...) and showed that PL is able to promote MSC expansion, to decrease the time required to reach confluence, and to increase CFU-F size, as compared to the FCS medium. Furthermore, we demonstrated that MSCs cultured in the presence of PL maintain their osteogenic, chondrogenic, and adipogenic differentiation properties and retain their immunosuppressive activity. Therefore, we propose that PL may be a powerful and safe substitute for FCS in development of tissue- and cellular-engineered products in clinical settings using MSCs.
间充质干细胞(MSCs)被视为新兴的“通用”细胞,各种使用MSCs的组织修复方案正在研发中。传统上,MSCs的体外扩增是在含有胎牛血清(FCS)的培养基中实现的,添加生长因子可使其扩增增加。然而,对于广泛的临床应用,必须尽量减少MSCs与FCS的接触,因为它可能是朊病毒或病毒传播的来源。因此,由于血小板是生长因子的天然来源,我们试图研究富含血小板血浆中获得的血小板裂解物(PL)对MSCs体外扩增的影响。通过传代培养过程,将人MSCs在添加FCS(±碱性成纤维细胞生长因子(bFGF))或PL的培养基中进行扩增。我们证明,含PL的培养基富含生长因子(血小板衍生生长因子(PDGFs)、碱性成纤维细胞生长因子(bFGF)、转化生长因子(TGF-β)、胰岛素样生长因子-1(IGF-1)……),并且表明与FCS培养基相比,PL能够促进MSCs扩增、减少达到汇合所需的时间并增加集落形成单位-成纤维细胞(CFU-F)的大小。此外,我们证明在PL存在下培养的MSCs保持其成骨、成软骨和脂肪生成分化特性,并保留其免疫抑制活性。因此,我们提出在临床环境中使用MSCs开发组织工程和细胞工程产品时,PL可能是FCS的一种强大且安全的替代品。